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Abstract
Objective The aim was to compare the efficacy and safety
of two antibiotic regimens in patients with diabetic foot
infections (DFIs).
Methods Data of a subset of patients enrolled in the
RELIEF trial with DFIs requiring surgery and antibiotics
were evaluated retrospectively. DFI was diagnosed on the
basis of the modified Wagner, University of Texas, and
PEDIS classification systems. Patients were randomized to
receive either intravenous/oral moxifloxacin (MXF,
N = 110) 400 mg q.d. or intravenous piperacillin/tazobac-
tam 4.0/0.5 g t.d.s. followed by oral amoxicillin/clavulanate
875/125 mg b.d. (PIP/TAZ–AMC, N = 96), for 7–21 days
until the end of treatment (EOT). The primary endpoint was
clinical cure rates in the per-protocol (PP) population at the
test-of-cure visit (TOC, 14–28 days after EOT).
Results There were no significant differences between the
demographic characteristics of PP patients in either
treatment group. At TOC, MXF and PIP/TAZ–AMC had
similar efficacy in both the PP and intent-to-treat (ITT)
populations: MXF: 76.4 % versus PIP/TAZ–AMC: 78.1 %;
95 % confidence interval (CI) -14.5 %, 9.0 % in the PP
population; MXF: 69.9 % versus PIP/TAZ–AMC: 69.1 %;
95 % CI -12.4 %, 12.1 % in the ITT population. The
overall bacteriological success rates were similar in both
treatment groups (MXF: 71.7 % versus PIP/TAZ–AMC:
71.8 %; 95 % CI -16.9 %, 10.7 %). A similar proportion
of patients (ITT population) experienced any adverse events
in both treatment groups (MXF: 30.9 % versus PIP/TAZ–
AMC: 31.8 %, respectively). Death occurred in three MXF-
treated patients and one PIP/TAZ–AMC-treated patient;
these were unrelated to the study drugs.
Conclusion Moxifloxacin has shown favorable safety and
efficacy profiles in DFI patients and could be an alternative
antibiotic therapy in the management of DFI. Clinical trial:
NCT00402727.
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Introduction
Diabetic foot infections (DFIs) are the most common cause
of hospitalization in people with diabetes, accounting for
more hospital bed days than any other diabetic complication
[1]. DFIs have a high burden of disease, for both the patient
and the health care system. Unless promptly treated, clinical
outcomes are poor, leading to impaired wound healing in
case of a diabetic foot ulcer, possible amputation of the
lower extremity, and significant financial costs [2, 3]. Dia-
betic patients with a DFI are around 50 times more likely to
be hospitalized and 150 times more likely to undergo lower
extremity amputation than diabetic patients without foot
infections [3, 4]. It has been estimated that around 1 million
patients with diabetes undergo limb amputation each year, a
surgical procedure that is associated with significant mor-
bidity and mortality, as well as major social, psychological,
and financial consequences [5, 6].
Peripheral arterial disease (PAD) is common in patients
with DFI, and is an important predictor of outcome [7]. For
this reason, the Infectious Diseases Society of America
(IDSA) has recommended the inclusion of PAD patients in
order to improve the quality of clinical trials evaluating
antimicrobial therapy in skin and soft tissue infection.
Despite this recommendation, however, few patients with
PAD have been included in DFI trials to date [8] and
outcome data in this population are lacking.
The most important pathogens causing DFIs are the
aerobic Gram-positive cocci (e.g., Staphylococcus aureus),
Gram-negative aerobes (e.g., Enterobacteriaceae), and
anaerobic pathogens (e.g., Bacteroides spp.) [3]. Most mild
to moderate infections are caused by Gram-positive bac-
teria, while more severe or chronic infections are usually
polymicrobial [3] and almost half can include anaerobes
[9]. The severity of DFIs has been classified broadly as
mild, moderate, or severe. However, a lack of consensus
and consistency in defining infection severity makes
comparison across published studies complicated.
Although various systems have been developed, no single
system has found universal acceptance. The most estab-
lished system of classification of ulceration, the Wagner
system [10], has been employed for more than 25 years,
but does not apply to infection severity, assessing only
ulcer depth and the presence of osteomyelitis or gangrene.
While the University of Texas diabetic wound classifica-
tion system has been validated in DFI and includes the
presence of infection, as well as ulcer depth and ischemia,
infection severity is, again, not assessed [11, 12]. At a more
recent international consensus conference, a system of
classification of diabetic foot ulcers [perfusion, extent/size,
depth/tissue loss, infection, and sensation (PEDIS)] was
developed that includes all the key elements of severity of
infection. The newer system has been adopted by the IDSA
and has been validated by Lavery et al. [13–15].
Optimal management of DFIs is multimodal, involving
surgical debridement, antibiotic therapy, scrupulous wound
care and offloading, glycemic control, and assessment and
treatment of underlying vascular disease if lower extremity
amputations are to be avoided [2]. In patients with deep
ulcers, immediate drainage with removal of all the necrotic
tissue should be considered and intravenous antibiotics are
started after material is obtained for culture. In the absence
of adequate microbiological information, the challenge for
clinicians is to select an appropriate empirical antibiotic
regimen because timely and proper management of dia-
betic foot infection together with surgery [14] is key to
prevent further complications. The patient’s previous
antibiotic exposure, the pathogens most commonly iso-
lated, and local rates of resistance should all be considered.
Fluoroquinolones, such as moxifloxacin (MXF), offer
possible advantages over other classes of antimicrobial
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agents for the empirical treatment of DFIs, due to their
broad spectrum of activity and pharmacodynamic proper-
ties [9, 16]. MXF, in particular, has an extended spectrum
of activity against aerobic and anaerobic pathogens [9, 16]
and can be given intravenously (IV) or orally (PO). The
switch between the two formulations is simple as they have
similar pharmacokinetic properties [17], and MXF pene-
trates well into inflamed subcutaneous tissues [18–20]. A
previous IV/PO study of MXF versus b-lactam/b-lacta-
mase inhibitor showed MXF to be effective and well tol-
erated in the treatment of complicated skin and skin
structure infections (cSSSIs) [21].
The rationale of the RELIEF study was to provide
additional data on the efficacy and safety of MXF in four
specific cSSSI diagnoses (major abscess, DFI, wound
infection, infected ischemic ulcer) [22]; the present paper
reports on the efficacy and safety of MXF versus a b-lac-
tam/b-lactamase inhibitor combination in the subgroup of
patients with DFI. The RELIEF study is unique in that it
addresses the limitations of previous studies by stratification
at inclusion, according to the severity of cSSSI and baseline
surgery. Moreover, in contrast to most earlier DFI studies,
patients with PAD were included. The combination of a
b-lactam antibiotic and a b-lactamase inhibitor (piperacillin/
tazobactam) was chosen as the comparator, as this combi-
nation is known to be effective in treating cSSSIs [23].
Methods
Study design and patients
The RELIEF study was a prospective, randomized, double-
dummy, double-blind, multinational, multicenter study
[22], involving adult men and women (C18 years old) with
a diagnosis of complicated bacterial skin and skin structure
infection of\21 days duration that required hospitalization
and initial parenteral antibiotic treatment for C48 h. DFI
patients were enrolled between 11th October 2006 and 9th
June 2008. Diagnoses were validated by an independent
Data Review Committee (DRC). All patients were strati-
fied before randomization according to the severity of ill-
ness (risk class I and II, or III and IV) using the Wilson
scoring system [24].
Patients had to have at least one of the following criteria:
involvement of deep soft tissue (e.g., fascia, muscle layer),
need for significant surgical intervention (e.g., surgical
drainage or drainage procedure guided by imaging and/or
debridement), or association with a significant underlying
disease that could complicate treatment response (e.g.,
cancer except basal- or squamous-cell skin cancers, cardiac,
hepatic, immunological, renal, respiratory, transplantation,
or vascular disease). Amputation of part of the foot could
have been performed in patients who had extensive infec-
tion and would not have benefited from other surgeries, but
patients could only be included if a cSSSI was still present
after completion of this surgery. All initial surgeries had to
be completed within 48 h after beginning infusion of the
antibiotics.
All diabetic patients had to have a DFI of mild to severe
infection intensity (PEDIS grade 2–4) during randomiza-
tion with or without osteomyelitis (patients with osteo-
myelitis could only be enrolled if the infected bone was
removed and if residual infection was still present). In
order to facilitate the comparison of this study with other
recent studies, all ulcers were also categorized according to
the University of Texas classification system [11]. As ini-
tial (emergency) surgery, including amputation of part of
the foot, within 48 h after inclusion was part of the
immediate treatment, post-amputation PEDIS infection
scores were retrospectively calculated for all patients to
confirm that the infection was still requiring antibiotic
treatment.
In all patients, glycemic control was measured by the
plasma level of glycated hemoglobin (HbA1c) values. To
describe the severity of infection, body temperature and
levels of inflammatory markers including C-reactive pro-
tein (CRP), procalcitonin (PCT), and white blood cell
count (WBC), were documented. Furthermore, wound
depth and type of wound care undertaken were also reg-
istered. The presence of peripheral neuropathy (assessed by
both vibration perception and light pressure testing) and
PAD [defined as ankle–brachial index (ABI) \0.9 and/or
foot pulses barely or not palpable] were also recorded.
Patients who had received therapy with a systemic or
topical antimicrobial for[24 h in the previous 7 days were
excluded from the study, unless they were considered to be
clinical failures (i.e., the patient showed no response or had
worsening of clinical signs and symptoms despite treat-
ment for C3 days) and a culture before enrolment showed
persistence of a pathogen that was susceptible to the study
drugs.
Study treatments
Patients received sequential IV/PO MXF, 400 mg q.d., plus
matching placebo or IV piperacillin/tazobactam (PIP/
TAZ), 4.0/0.5 g t.d.s., followed by PO amoxicillin/clavu-
lanic acid (AMC) 875/125 mg b.d. They were treated for a
minimum of 7 and a maximum of 21 days. The switch
from IV to PO drug was at the investigator’s discretion,
provided the patient was improving on IV therapy, had no
fever, that gastrointestinal absorption was adequate, and
the patient had received IV study drug for at least 48 h. The
total duration of therapy was also at the investigator’s
discretion.
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Assessments
Clinical efficacy was assessed during treatment (days 3–5),
at the end of treatment (EOT, 7–21 days after inclusion),
and at the test-of-cure visit (TOC, 14–28 days after EOT).
The primary efficacy variable was clinical response at TOC
as assessed by the independent DRC. Photographs of skin
lesions were taken at each assessment and were used by the
DRC, together with blinded patient data, to evaluate clin-
ical response to the study drug at TOC. Patients were
considered as clinical failures at any visit who had insuf-
ficient lessening of the clinical signs and symptoms of
infection such that additional or alternative antimicrobial
therapy was required (with or without additional surgery).
Clinical cures/successes were patients considered to be
cured at TOC and who were not considered as failures at
EOT. Patients whose outcome was considered as clinical
failure at EOT were counted in the total number of clinical
failures at TOC. Safety assessment was based on physical
examination, vital signs, ECG, adverse events (AEs), and
standard laboratory tests throughout the study.
Patient populations
The RELIEF study had a non-inferiority design [22] and
the current analysis is based on the subpopulation of
patients with DFI in the RELIEF study [25]. The main
analysis population was the per-protocol (PP) population,
consisting of all patients who had received the study drug
for C72 h (in case of clinical failure) or 7 full days (in case
of success), had received C48 h of IV therapy, had docu-
mented compliance of C80 % with study medication, had
no protocol violations influencing treatment efficacy, and
for whom a clinical evaluation at TOC other than ‘inde-
terminate’ (subjects in whom a clinical assessment could
not be determined as improvement, resolution, or failure)
was available. Confirmatory and safety analyses were
carried out on the intent-to-treat (ITT) population (all
randomized patients who received at least one dose of
study drug and had at least one observation after taking
study medication).
Bacteriological evaluations were performed using the
microbiologically valid (MBV) population (all PP patients
for whom at least one causative organism could be cultured
from an appropriate specimen within 48 h before or fol-
lowing randomization and a bacteriological evaluation at
TOC other than ‘indeterminate’ was available). Confir-
matory analyses were carried out on the ITT with organ-
isms population, which included all patients in the ITT
population for whom at least one causative organism could
be cultured from an appropriate specimen within 48 h
before or following randomization.
Bacteriological assessments
Bacteriological evaluation was performed at enrolment,
during therapy (days 3–5), at EOT, and at TOC. Biospec-
imens were taken by needle aspiration, tissue biopsy, or
curettage for culture, identification of bacteria, and for
susceptibility testing against a variety of antibiotics,
including study drugs. In addition, susceptibility to oxa-
cillin was tested when staphylococci were isolated and
extended-spectrum beta-lactamase (ESBL) activity was
determined for Enterobacteriaceae species. Acceptable
culture specimens included skin biopsy, curettage of the
wound base after debridement, tissue or bone biopsy,
aspiration of purulent secretions, or a leading-edge needle
aspiration for subjects with cellulitis. Cultures should not
have been obtained using a swab. All cultured organisms
underwent genus and species identification at the central
microbiology laboratory. In subjects with initial baseline-
positive blood cultures, blood cultures were repeated until
the result was negative.
The study microbiologist reviewed all information
before un-blinding the patients according to whether bac-
teria were colonizing in nature, whether they were part of
the normal flora, or whether they likely played a patho-
genic role based on its nature and quantitative culture
results. Criteria indicating infection rather than coloniza-
tion included growth of the organism from the deep tissue
in the setting of inflammation and purulent drainage [14]
and Gram-stained smear of the wound showing neutrophils
and organisms morphologically compatible with those
grown in culture.
Statistical methods
Treatment groups were compared using the Mantel–
Haenszel estimates and 95 % confidence intervals (CIs)
for differences in the cure rates at TOC. For the PP analyses
of the clinical and bacteriological responses, the treatment
comparisons were performed as ‘‘success’’ versus ‘‘non-
success’’ (missing or indeterminate outcomes were not
allowed in the PP population). For the ITT analyses, a
comparison of ‘‘success’’ versus ‘‘non-success’’ was per-
formed; additionally, an analysis of ‘‘success’’ versus
‘‘failure’’ was compared. Statistical analyses were stratified
by the severity of illness based on the Wilson scoring sys-
tem and the presence or absence of a cSSSI-related surgical
procedure prior to or scheduled to take place within 48 h of
study entry. Non-inferiority of MXF was demonstrated if
the lower limit of the 95 % CI was above -10 %. As the
RELIEF study was not powered to look at subgroups, the
95 % CIs presented here are exploratory in nature. Adverse
events were classified according to MedDRA code and their
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severity and relationship to study drug assessment. Vital
signs and laboratory data were analyzed descriptively.
Results
Patient disposition
A total of 233 patients with a DFI were randomized into the
study (ITT population), of whom 206 were valid for the PP
analysis (MXF = 110, PIP/TAZ–AMC = 96). The patient
disposition is shown in Fig. 1. There were no significant
differences between the demographic characteristics of PP
patients in either treatment group (Table 1), except that
there were more men in the PIP/TAZ–AMC group and the
mean glycosylated hemoglobin (HbA1c) levels were higher
in the MXF arm. Patients in both study arms were over-
weight, had elevated CRP and PCT levels, and more than
80 % were febrile. HbA1c levels were considerably higher
than those observed in the overall RELIEF population
(7.0–7.4 %) [22], but are consistent with other studies in
patients with DFI [26, 27]. PAD was evident in over 65 %
of all patients, out of whom 129 (62.6 %) had barely or
non-palpable pulses in both dorsalis pedis and posterior
tibialis arteries, and almost half had peripheral neuropathy
(Table 1). Most infection types ([87 %) were community
acquired (CA). At baseline, most patients had moderate to
severe DFIs, with a PEDIS infection score of 3 or 4. Initial
surgeries (most commonly amputation or extensive
debridement) were carried out on 150 patients (MXF:
70.9 % versus PIP/TAZ: 75.0 %). Although the baseline
pre-amputation PEDIS infection scores were similar in the
two groups of patients (Table 1), it was observed that,
numerically, but not statistically significantly, more
patients in the MXF arm had an amputation as initial
(\48 h after randomization) surgery (MXF: n = 51,
46.4 % and PIP/TAZ–AMC: n = 33, 34.3 %). PEDIS
infection scores were calculated post-amputation to assess
whether this had introduced a bias. More patients in the
MXF arm had a calculated PEDIS score of 3 (n = 29,
56.9 %) than in the PIP/TAZ–AMC arm (n = 13, 39.4 %)
post-amputation. A similar number of patients in each
treatment arm had mild infection, i.e., PEDIS score of 2
(MXF: n = 22, 43.1 % and PIP/TAZ–AMC: n = 20,
60.6 %), while none had a severe infection (i.e., PEDIS
score of 4) following amputation in either arm. The mean
[standard deviation (SD)] duration of combined IV/PO
therapy was similar, being 14.5 (4.5) days in the MXF and
14.2 (4.4) days in the PIP/TAZ–AMC groups, respectively.
There was no significant difference between the two arms
regarding the length of either PO or IV treatments. Intra-
venous infusion lasted for 8.1 ± 4.1 days in the MXF
group and 7.5 ± 3.3 days in the PIP/TAZ–AMC group; PO
administration of drugs lasted for 8.1 ± 3.2 days in the
MXF group and 8.4 ± 3.1 days in the PIP/TAZ–AMC
group. The number of patients who received other antibi-
otics before treatment with study drugs was similarly low
in the MXF (8.2 %) and PIP/TAZ–AMC (8.3 %) treatment
groups, respectively.
Baseline bacteriology
Particular attention was paid as to whether the organisms
isolated represented colonizers or pathogens. The presented
Fig. 1 Disposition of patients
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data in this paper refer to pathogenic bacteria. A total of 92
MXF-treated and 85 PIP/TAZ–AMC-treated MBV patients
had 347 pathogenic organisms isolated at baseline (MXF:
177, PIP/TAZ–AMC: 170), with similar microbiological
profiles seen across the two treatment groups. The most
commonly isolated organisms as a percentage of all
organisms isolated were: methicillin-susceptible Staphylo-
coccus aureus (MSSA) (MXF: 53, 29.9 %; PIP/TAZ–
AMC: 57, 33.5 %), Enterococcus faecalis (MXF: 30,
16.9 %; PIP/TAZ–AMC: 29, 17.1 %), methicillin-resistant
S. aureus (MRSA) (MXF: 11, 6.2 %; PIP/TAZ–AMC: 12,
7.1 %), non-ESBL-producing Escherichia coli (MXF: 8,
4.5 %; PIP/TAZ–AMC: 11, 6.5 %), Bacteroides fragilis
(MXF: 3, 1.7 %; PIP/TAZ–AMC: 4, 2.4 %), Streptococcus
pyogenes (MXF: 3, 1.7 %; PIP/TAZ–AMC: 2, 1.2 %), and
ESBL-producing E. coli (MXF: 1, 0.6 %; PIP/TAZ–AMC:
1, 0.6 %). Polymicrobial infections were common,
Table 1 Demographic and disease characteristics of patients at







Sex, male, n (%) 61 (55.5) 69 (71.9)
Mean age (years) (SD) 58.9 (10.2) 59.5 (10.1)
Mean BMI, kg/m2 (SD) 28.9 (5.7) 28.6 (4.7)
Temperature [38 C, n (%) 98 (89.1) 79 (82.3)
Mean WBC, 109/L (SD) 10.0 (4.0) 9.3 (3.8)
Mean HbA1c (%) (SD) 9.7 (2.5) 9.0 (2.1)
Mean CRP, mg/L (SD) 8.3 (8.8) 8.7 (8.4)
Mean PCT, ng/ml (SD) 0.2 (0.3) 0.2 (0.6)
Peripheral neuropathy, n (%)
Vibration perception test—negativec 44 (41.5) 48 (51.6)
Light pressure test (plantar surface of
heel)—negatived
52 (49.5) 44 (47.8)
Peripheral arterial diseasea, n (%) 72 (65.5) 68 (70.8)
ABI \0.9 46 (41.8) 42 (43.8)
Absent or barely palpable dorsalis
pedis and posterior tibialis pulses
66 (60.0) 63 (65.6)
Infection type, n (%)
Community acquired 96 (87.3) 87 (90.6)
Hospital acquired 14 (12.7) 9 (9.4)
Mean time since occurrence of
symptoms (days) (SD)
9.5 (5.4) 9.2 (5.6)
Pre-therapy antibiotic use, n (%) 9 (8.2) 8 (8.3)
Mean lesion area (cm2) (SD) 46.9 (66.4) 35.1 (48.5)
Deepest tissue layer infected, n (%)
Dermis 10 (9.1) 6 (6.3)
Subcutaneous fat 12 (10.9) 4 (4.2)
Fascia, muscle, or deeper 88 (80.0) 86 (89.6)
Type of surgery during first 48 hb, n (%)
No surgery 32 (29.1) 24 (25.0)
Abscess drainage 28 (25.5) 31 (32.3)
Local debridement 21 (19.1) 17 (17.7)
Extensive debridement 32 (29.1) 38 (39.6)
Primary closure 12 (10.9) 8 (8.3)
Amputation 51 (46.4) 33 (34.4)
Graft surgery 0 (–) 1 (1.0)
Removal of infected bone area 21 (19.1) 19 (19.8)
Revascularization 1 (0.9) 1 (1.0)
Necrectomy 0 (–) 1 (1.0)
University of Texas wound classificatione, n (%)
Grade 0, Infected 0 (–) 1 (1.1)
Grade 0, Ischemica 1 (0.9) 0 (–)
Grade I, Infected 4 (3.7) 1 (1.1)
Grade I, Ischemica 11 (10.3) 8 (8.5)
Grade II, Infected 16 (15.0) 14 (14.9)
Grade II, Ischemica 45 (42.1) 43 (45.7)







Grade III, Ischemica 21 (19.6) 25 (26.6)
Wilson score, mean (SD) 100.6 (21.9) 103.5 (22.5)
Risk class I, n (%) 5 (4.5) 4 (4.2)
Risk class II, n (%) 20 (18.2) 8 (8.3)
Risk class III, n (%) 34 (30.9) 33 (34.4)
Risk class IV, n (%) 51 (46.4) 51 (53.1)
Baseline PEDIS infection score classification of all patientse, n (%)
2 (Mild) 14 (13.1) 8 (8.5)
3 (Moderate) 87 (81.3) 81 (86.2)
4 (Severe) 6 (5.6) 5 (5.3)
Baseline PEDIS infection score classification before amputationf,
n (%)
2 (Mild) 1 (2.0) 0 (0.0)
3 (Moderate) 47 (92.2) 31 (93.9)
4 (Severe) 3 (5.9) 2 (6.1)
ABI ankle–brachial index; BMI body mass index; CRP C-reactive
protein; HbA1c glycosylated hemoglobin; MXF moxifloxacin; PCT
procalcitonin, PEDIS perfusion, extent/size, depth/tissue loss, infec-
tion, and sensation; PIP/TAZ–AMC piperacillin/tazobactam–amoxi-
cillin/clavulanic acid; SD standard deviation; WBC white blood cell
count
a Defined as ABI \0.9 and/or foot pulses barely or not palpable; foot
pulses as barely or not palpable were examined in the dorsalis pedis
and posterior tibialis arteries
b Patients could have C1 surgical procedure
c n = 106 MXF, n = 93 PIP/TAZ–AMC
d n = 105 MXF, n = 92 PIP/TAZ–AMC
e n = 107 MXF, n = 94 PIP/TAZ–AMC
f Patients (n = 51 MXF, n = 33 PIP/TAZ–AMC) exclusively with
amputation as initial surgery (either prior to enrolment or within 48 h
after the start of study medication)
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occurring in more than half of all patients (MXF: 60.9 %;
PIP/TAZ–AMC: 62.3 %).
Clinical efficacy
Clinical cure rates were similar between treatment groups
(Fig. 2). At TOC, MXF and PIP/TAZ–AMC had similar
efficacy in both the PP and ITT populations (MXF: 76.4 %
versus PIP/TAZ–AMC: 78.1 %; 95 % CI -14.5 %, 9.0 %
in the PP population; MXF: 69.9 % versus PIP/TAZ–
AMC: 69.1 %; 95 % CI -12.4 %, 12.1 % in the ITT
population). Similar results were seen in patients of the
MBV population (MXF: 69/92, 75.0 % versus PIP/TAZ–
AMC: 64/85, 75.3 %; 95 % CI -15.8 %, 10.6 %) and of
the ITT with organisms population (MXF: 71/102, 69.6 %
versus PIP/TAZ–AMC: 65/96, 67.7 %; 95 % CI -13.0 %,
14.1 %). Good clinical efficacy was seen across the range
of infection severities, as measured by the University of
Texas wound classification, baseline PEDIS infection
scores, or the Wilson classification system (Table 2).
Additional surgeries [48 h after the start of therapy
(including amputation) were carried out on 20.9 % of
MXF-treated and 25.0 % of PIP/TAZ–AMC-treated
patients (PP populations). Of these, fewer MXF versus PIP/
TAZ–AMC patients required amputation (8.2 versus
16.7 %, respectively), but these differences were not sta-
tistically different.
Bacteriological response
The susceptibility to the administered antibiotics of the
most common bacteria isolated in our DFI patients is
shown in Table 3. The most prevalent causative species
(MSSA) was susceptible to both antibiotics used, while the
second most frequently isolated species (E. faecalis) was
resistant to both MXF and PIP/TAZ in a small percentage
of cases [i.e., 5 out of 34 isolates (14.7 %) and 5 out of 33
isolates (15.1 %) in both treatment groups, respectively].
Overall the proportion of patients with bacteriological
success in the MBV (Table 4) population were similar
across treatment arms (MXF: 71.7 % versus PIP/TAZ–
AMC: 71.8 %) and no difference was found between
treatment groups (95 % CI -16.9 %, 10.7 %). Data from
patients in the ITT with organisms population support that
MXF was as effective as PIP/TAZ–AMC (95 % CI
-13.0 %, 14.6 %). A similar bacteriological outcome was
observed for the most commonly isolated pathogens
between the two treatment arms (Table 4). Eradication of
MSSA was numerically higher with MXF treatment. In the
small number of patients who had MRSA, the proportion
achieving eradication for this species was similar. The
proportion of patients achieving bacteriological eradication
Fig. 2 Clinical cure at the test-of-cure visit (TOC) in the per-protocol
(PP) and intent-to-treat (ITT) patient populations. CI confidence
interval, ITT intent-to-treat, MXF moxifloxacin, PIP/TAZ–AMC
piperacillin/tazobactam–amoxicillin/clavulanic acid, PP per-protocol
Table 2 Clinical success by disease severity scoring system
(per-protocol population)
MXFb, n/N (%) PIP/TAZ–AMCb,
n/N (%)
Texas wound classification
Grade 0 0/1 (0) 1/1 (100)
Infected 1/1 (100)
Ischemica 0/1 (0)
Grade I 11/15 (73.3) 7/9 (77.8)
Infected 3/4 (75.0) 1/1 (100)
Ischemica 8/11 (72.7) 6/8 (75.0)
Grade II 45/61 (73.8) 47/57 (82.5)
Infected 12/16 (75.0) 14/14 (100)
Ischemica 33/45 (73.3) 33/43 (76.7)
Grade III 25/30 (83.3) 18/27 (66.7)
Infected 9/9 (100) 2/2 (100)
Ischemica 16/21 (76.2) 16/25 (64.0)
PEDIS infection score classification prior to any surgery
2 (Mild) 12/14 (85.7) 6/8 (75.0)
3 (Moderate) 66/87 (75.9) 64/81 (79.0)
4 (Severe) 3/6 (50.0) 3/5 (60.0)
Wilson classification
Risk class I 4/5 (80.0) 4/4 (100)
Risk class II 15/20 (75.0) 7/8 (87.5)
Risk class III 30/34 (88.2) 28/33 (84.8)
Risk class IV 35/51 (68.6) 36/51 (70.6)
MXF moxifloxacin, PIP/TAZ–AMC piperacillin/tazobactam–amoxi-
cillin/clavulanic acid
n/N = number of patients with clinical cure/total number of patients
P [ 0.05 in all cases, Cochran–Mantel–Haenszel test
a Defined as ABI \0.9 and/or foot pulses barely or not palpable
b MXF: N = 107; PIP/TAZ–AMC: N = 94
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of monomicrobial (MXF: 25/36, 69.4 % versus PIP/TAZ–
AMC: 23/32, 71.9 %) or polymicrobial infections (MXF:
43/56, 76.8 % versus PIP/TAZ–AMC: 38/53, 71.7 %) were
relatively similar between treatment groups. The lowest
percentages (\70 %) of bacteriological success among the
most frequent organisms were observed for infections with
E. faecalis for both treatment groups; this species was
mainly isolated from polymicrobial infections.
The emergence of resistant bacteria with moxifloxacin
treatment was rare while on therapy or post-therapy in both
treatment groups, and it was only seen for one Klebsiella
pneumoniae (non-ESBL) isolate (pre-therapy: MIC90 =
0.12 mg/L, during therapy: MIC90 = 8.0 mg/L, EOT:
MIC90 = 8.0 mg/L) and one Acinetobacter baumannii
isolate (pre-therapy: MIC90 = 1.0 mg/L, during therapy:
MIC90 = 2.0 mg/L, EOT: MIC90 = 8.0 mg/L).
Table 3 Pre-therapy minimum inhibitory concentrations of study drugs against common pathogens (ITT with pathogens population)
N MXF (mg/L) PIP/TAZ (mg/L) AMC (mg/L)
MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90 Range
Staphylococcus aureus
Methicillin-susceptible 125 0.03 0.06 B0.015–4.0 1.0 2.0 0.5–2.0 0.50 1.0 B0.06–2.0
Methicillin-resistant 27 2.0 8.0 0.12–8.0 16.0 [128 4.0 to [128 8.0 [32.0 2.0 to [32.0
Enterococcus faecalis 67 0.25 16.0 0.12–16.0 4.0 8.0 2.0 to [128 1.0 1.0 0.25–32.0
Escherichia coli
Non-ESBL-producing 20 0.03 32.0 0.03 to [32.0 2.0 2.0 0.5–2.0 4.0 8.0 2.0–8.0
Bacteroides fragilis 10 0.5 2.0 0.5–4.0 0.25 0.5 0.12–1.0 – – –
ESBL extended-spectrum beta-lactamase, N total number of isolates, ITT intent-to-treat, MXF moxifloxacin, PIP/TAZ–AMC piperacillin/tazo-
bactam–amoxicillin/clavulanic acid; Streptococcus pyogenes (n = 6): for MXF: MIC50 0.12, MIC90 0.25, range 0.12–0.25; for PIP/TAZ: MIC50
B0.25, MIC90 B0.25, range B0.25 to B0.25; for AMC: MIC50 B0.06, MIC90 B0.06, range B0.06 to B0.06; Escherichia coli ESBL-producing
(n = 3): for MXF: MIC90 C32.0; for PIP/TAZ: MIC90 = 16.0; for AMC: MIC90 = 16.0
Table 4 Bacteriological success overall and by key organisms
Bacteriological success by patients
MXF, n/N (%) PIP/TAZ–AMC,
n/N (%)
MBV 66/92 (71.7) 61/85 (71.8)
ITT with organisms 69/102 (67.6) 62/96 (64.6)
Bacteriological success by key organism (MBV population)a
Staphylococcus aureus
Methicillin-susceptible 43/53 (81.1) 39/57 (68.4)
Methicillin-resistant 8/11 (72.7) 10/12 (83.3)
Streptococcus pyogenes 3/3 (100) 2/2 (100)
Enterococcus faecalis 19/30 (63.3) 20/29 (69.0)
Escherichia coli
ESBL-producing 1/1 (100) 1/1 (100)
Non-ESBL-producing 6/8 (75.0) 8/11 (72.7)
Bacteroides fragilis 3/3 (100) 3/4 (75.0)
ITT intent-to-treat, MBV microbiologically valid, ESBL extended-
spectrum beta-lactamase, MXF moxifloxacin, PIP/TAZ–AMC piper-
acillin/tazobactam–amoxicillin/clavulanic acid
a n/N = number organisms with eradication or presumed eradication/
total number of organisms isolated
Table 5 Overview of treatment-emergent adverse events in patients










Adverse event (AE) 38 (30.9) 35 (31.8) 0.89
Diarrhea 1 (0.8) 4 (3.6)
Gangrene 2 (1.6) 3 (2.7)
Nausea 2 (1.6) 3 (2.7)
Blood creatinine increased 3 (2.4) 1 (0.9)
Creatinine renal clearance
decreased
3 (2.4) 1 (0.9)
Electrocardiogram QT
prolonged
3 (2.4) 1 (0.9)
Pyrexia 1 (0.8) 3 (2.7)
Abscess limb 0 (–) 3 (2.7)
Insomnia 3 (2.4) 2 (1.8)
Hypertension 5 (4.1) 1 (0.9)
Drug-related AE 12 (9.8) 11 (10.0) 1.00
Premature discontinuation
due to AE
5 (4.1) 2 (1.8) 0.45
Serious AE 13 (10.6) 10 (9.1) 0.83
Drug-related SAE 2 (1.6) 0 (0.0)
Premature discontinuation
due to drug-related SAE
2 (1.6) 0 (0.0)
Deaths 3 (2.4) 1 (0.9) 0.62
AE adverse event, SAE serious adverse event, ITT intent-to-treat,
MXF moxifloxacin, PIP/TAZ–AMC piperacillin/tazobactam–amoxi-
cillin/clavulanic acid
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Safety
The total numbers of patients with a DFI experiencing any
adverse event were comparable between the MXF [38
(30.9 %)] and PIP/TAZ–AMC [35 (31.8 %)] groups
(Table 5). Only two moxifloxacin-treated patients (1.6 %)
experienced drug-related serious adverse events (SADR)
and none (0 %) in the other treatment arm; those two
reported SADR cases in the MXF arm occurred as
asymptomatic prolongation of ECG QT interval with per-
manent discontinuation of the study drug. Death occurred
in three MXF (2.4 %) and one PIP/TAZ–AMC (0.9 %)
treatment patients and none of these was reported to be
drug-related (three MXF patients died due to respiratory
failure, pulmonary embolism, and cardiovascular and renal
failure, and one PIP/TAZ–AMC patient died due to arterial
thromboembolism).
Discussion
MXF IV/PO therapy had similar efficacy compared with
PIP/TAZ–AMC therapy in patients with moderate to severe
DFI in a randomized double-blind trial in which patients
were prospectively stratified according to the severity of
illness and the need for surgery. Previous DFI trials have
failed to document important disease parameters and
baseline data such as infection severity and wound classi-
fication at study entry, making comparison between studies
difficult [28–31]. In contrast, the patients in the present
study were well characterized, with a range of important
baseline characteristics such as body mass index (BMI),
degree of glycemic control, levels of inflammatory markers,
presence of limb ischemia, wound type and care, and
severity of infection being documented. These parameters
have been highlighted in a recent review as key parameters
to be included in order to improve the quality of future DFI
studies [32].
Patients in the current study were recruited across a range
of infection severities, though most of the DFI patients
([80 %) had moderate to severe infections with a PEDIS
infection score of 3 and could be considered as difficult-to-
treat patients. As expected, a relatively high number of
patients required initial surgery, one of the cornerstones in
the treatment of severe foot infections, which could have
introduced bias. However, the post-initial surgery PEDIS
infection scores did not differ between both treatment arms.
An additional strength of the current study is that the
majority ([65 %) of the RELIEF study patients with a DFI
had also signs of PAD. PAD is present in around half of all
patients with foot ulcers [7], yet, a number of earlier clinical
trials of antibiotics in DFIs enrolled few PAD patients
[33, 34] or excluded those with critical limb ischemia
[29, 31] or PAD requiring revascularization [23]. In the
large-scale Eurodiale study, the outcome of DFIs in patients
without PAD was relatively good, but particularly poor
results were obtained in DFI patients with PAD [35]. As pre-
viously demonstrated, treatment with IV or PO moxifloxacin in
DFI patients achieves a concentration well above MIC90 for
most pathogenic bacteria in peri-necrotic limb tissue [19],
suggesting that PK/PD properties of moxifloxacin are able to
overcome the potential lack of perfusion due to PAD.
Whether the antibiotic agent reaches its site-of-action
with sufficiently high levels is a critical point in DFI
patients with PAD and limb ischemia, and has been inves-
tigated in previous studies [36, 37]. For example, Zammit
et al. [38] have investigated the impact of increasing
severity of PAD on the tissue concentration of gentamicin
in patients with ischemic ulcers. These authors have found a
strong inverse correlation between PAD severity and local
limb tissue concentration of the antibiotic drug, suggesting
that local blood flow regulation is an important determinant
of drug efficacy. Similarly, the penetration of ceftazidime
into bone and soft tissues was found to be correlated in
another study with the degree of tissue perfusion in both
diabetic and non-diabetic patients [34]. Moreover, dimin-
ished and impaired microcirculation could well be a com-
plicating factor for why DFI patients require antibiotic
treatment for a long period of time (i.e., the mean duration
of therapy in the current study was[14 days). There were
17 patients in nine different study centers who had critical
limb ischemia with an ABI \0.5 (12 MXF patients and five
PIP/TAZ–AMC patients). Only one of these patients
underwent a revascularization procedure during the study
period, suggesting that the treatment of PAD was in our
patients suboptimal and that better results may have been
obtained with a more aggressive approach.
The burden of disease due to the DFI was high in our
study, with 53 % of all patients undergoing an amputation
either as initial treatment or during the course of the
treatment. Patients in this study had a severe condition at
baseline due to poor glycemic control (mean HbA1c of
nearly 10 %) and elevated inflammatory markers (WBC,
CRP, and PCT). Earlier diagnosis and treatment of a dia-
betic foot ulcer with better glycemic control or earlier
recognition of the presence of infection in these patients
with prompt institution of appropriate multidisciplinary
management might have prevented the development of a
more severe infection in many of our patients.
In the current study, both MXF and PIP/TAZ–AMC had
relatively high clinical efficacy rates with respect to clinical
cure at TOC across all patient populations and sequential
IV/PO MXF was as effective as IV/PO PIP/TAZ–AMC,
thus, confirming the results of previous studies [21, 39].
To date, no single agent has been found to be the most
effective for the treatment of moderate to severe DFI and,
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usually, therapy is selected on an empirical basis, either a
broad-spectrum agent or a combination of agents that
provide a broad spectrum [21]. The current results with
MXF are particularly promising, as not only does MXF
offer a broad spectrum of activity, permitting the agent to
be used in monotherapy, but its IV and oral formulations
are similar in their pharmacokinetic properties, so that the
switch between IV and PO is simple.
The range of baseline pathogens isolated and infection
types was as anticipated, with the most commonly occur-
ring pathogen being S. aureus (approximately 30 %),
although the number of isolated anaerobic bacteria was
quite low. Polymicrobial infections become more likely
with increasing severity and chronicity of the diabetic foot
ulcer [40], and these occurred in more than half of our
patients. Bacteriological eradication was high in both
treatment groups; somewhat higher eradication was seen for
MXF versus PIP/TAZ–AMC in polymicrobial infections
(76.8 versus 69.8 %). Several previous studies reported
higher levels of MRSA infection (30–50 %) [5, 41, 42] than
those seen in the RELIEF study (6–7 %). However, the vast
majority of the DFIs treated in this study were community-
acquired infections, while in most European countries
MRSA infections tend to occur more commonly in patients
who have been in hospital; moreover, regional differences
in MRSA prevalence might also play a role. Nevertheless,
MRSA infections are not necessarily more severe than
MSSA infections [43]. In this study, MRSA might have
been present simply as a colonizer, particularly in the
patients in whom MRSA was isolated but who experienced
a clinical cure without a specific anti-MRSA agent (notably
when there was a low or a lack of susceptibility of MRSA to
either MXF or PIP/TAZ–AMC).
Both treatments were well tolerated with similar per-
centages of patients experiencing any adverse events or
drug-related serious adverse events at low frequencies.
None of the deaths reported in this clinical trial was drug-
related.
Gyssens et al. [22] provide an extensive commentary on
the strengths and weaknesses of the RELIEF study design,
of which the pre-randomization stratification is identified
as a key strength and a feature which has not, to date, been
included in the design of other skin and soft tissue infection
clinical trials. The strict methodology used in the RELIEF
study provided an in-depth and accurate assessment of
patients and disease characteristics and assessment by a
blinded DRC, prospective use of the Wilson Risk Class,
and standardized photo assessment of lesions all helped to
remove investigator bias [22]. We acknowledge that sub-
group analysis is associated with limitations; in particular,
the relatively low number of patients with diabetic foot
infections in each treatment arm results in an insufficient
statistical power and limits the interpretation of the results
of this study to the patient population with DFI in general.
Therefore, these results should be interpreted cautiously.
In conclusion, IV/PO MXF monotherapy is clinically
and bacteriologically similar to PIP/TAZ–AMC in DFI and
is an effective and valuable treatment option for patients
with moderate to severe DFI. Moxifloxacin treatment was
well tolerated; therefore, in combination with surgery,
sequential MXF monotherapy is an appropriate treatment
choice for DFI patients with a range of severities, partic-
ularly for those with polymicrobial infections. Although
infection was cured in the majority of patients, many
patients underwent surgery and/or an (initial) amputation,
highlighting the importance of early recognition and sub-
sequent prompt treatment of DFIs.
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